Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRS3 | P32247 | 1/20 | 0.47 |
| ▸ | PANK3 | Q9H999 | 6/20 | 0.47 |
| ▸ | P2RY12 | Q9H244 | 4/20 | 0.43 |
| ▸ | ME2 | P23368 | 2/20 | 0.43 |
| ▸ | ME1 | P48163 | 2/20 | 0.43 |
| ▸ | ME3 | Q16798 | 2/20 | 0.43 |
| ▸ | HRH2 | P25021 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3334079 | 0.82 | KDM4E (0.58) | PANK3ME2ME1ME3HRH2 | |
| SCHEMBL3331527 | 0.79 | MEN1 (0.55) | PANK3ME2ME1ME3HRH2 | |
| SCHEMBL3338157 | 0.79 | KDM4E (0.58) | PANK3SMN1; SMN2HPGDNPSR1HSD17B10 | |
| SCHEMBL3333658 | 0.78 | ME2 (0.48) | PANK3ME2ME1ME3HRH2 | |
| SCHEMBL3334743 | 0.78 | THRB (0.52) | ME2ME1ME3HRH2HRH1 | |
| SCHEMBL3335793 | 0.76 | ME2 (0.47) | PANK3ME2ME1ME3HRH2 | |
| SCHEMBL3334723 | 0.74 | KDM4E (0.60) | PANK3SMN1; SMN2HPGDNPSR1HSD17B10 | |
| SCHEMBL3340041 | 0.74 | KDM4E (0.57) | PANK3ME2ME1ME3SMN1; SMN2 | |
| SCHEMBL2531455 | 0.74 | TRPV1 (0.46) | P2RY12SMN1; SMN2HPGDHSD17B10L3MBTL1 | |
| SCHEMBL3331511 | 0.73 | HPGD (0.50) | PANK3ME2ME1ME3HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | claimed |
| CN-101679261-A | Piperazine and piperidine mglur5 potentiators | ASTRAZENECA AB | 2010-03-24 | — | — | CN | claimed |
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | GRM5, GRM1, GRM2 | BRS3 136/4885PANK3 3656/4885P2RY12 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.